ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.163,52
-0,41%
S&P 500
5.464,62
-0,16%
Dow Jones
39.150,33
0,04%
Euro vs US Dollar
1,06925
0,00%
Bitcoin
64.066,99
-0,28%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Satsuma Pharmaceuticals Inc (STSA)

  7. Satsuma Pharmaceuticals Inc (STSA) News

STSA

Satsuma Pharmaceuticals (STSA)

Satsuma Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:STSA
DatumZeitQuelleÜberschriftSymbolFirma
20/06/202319h03Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:STSASatsuma Pharmaceuticals Inc
15/06/202314h00GlobeNewswire Inc.Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society’s 65th Annual Scientific MeetingNASDAQ:STSASatsuma Pharmaceuticals Inc
12/06/202323h01Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:STSASatsuma Pharmaceuticals Inc
09/06/202312h04Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:STSASatsuma Pharmaceuticals Inc
09/06/202312h04Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:STSASatsuma Pharmaceuticals Inc
08/06/202322h46Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:STSASatsuma Pharmaceuticals Inc
08/06/202322h44Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:STSASatsuma Pharmaceuticals Inc
08/06/202322h44Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:STSASatsuma Pharmaceuticals Inc
08/06/202322h38Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:STSASatsuma Pharmaceuticals Inc
08/06/202322h33Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:STSASatsuma Pharmaceuticals Inc
08/06/202322h32Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:STSASatsuma Pharmaceuticals Inc
08/06/202322h31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:STSASatsuma Pharmaceuticals Inc
08/06/202322h25Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:STSASatsuma Pharmaceuticals Inc
08/06/202315h23Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:STSASatsuma Pharmaceuticals Inc
08/06/202315h22Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:STSASatsuma Pharmaceuticals Inc
08/06/202315h20Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:STSASatsuma Pharmaceuticals Inc
08/06/202315h19Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:STSASatsuma Pharmaceuticals Inc
08/06/202315h18Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:STSASatsuma Pharmaceuticals Inc
08/06/202315h18Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:STSASatsuma Pharmaceuticals Inc
08/06/202315h17Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:STSASatsuma Pharmaceuticals Inc
08/06/202315h17Edgar (US Regulatory)Amended Statement of Ownership: Private Transaction (sc 13e3/a)NASDAQ:STSASatsuma Pharmaceuticals Inc
08/06/202315h17Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:STSASatsuma Pharmaceuticals Inc
08/06/202315h15Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:STSASatsuma Pharmaceuticals Inc
08/06/202315h14Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:STSASatsuma Pharmaceuticals Inc
08/06/202315h13Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:STSASatsuma Pharmaceuticals Inc
08/06/202315h12Edgar (US Regulatory)Amended Statement of Ownership: Private Transaction (sc 13e3/a)NASDAQ:STSASatsuma Pharmaceuticals Inc
31/05/202312h04Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:STSASatsuma Pharmaceuticals Inc
31/05/202312h03Edgar (US Regulatory)Amended Statement of Ownership: Private Transaction (sc 13e3/a)NASDAQ:STSASatsuma Pharmaceuticals Inc
26/05/202312h40Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:STSASatsuma Pharmaceuticals Inc
25/05/202312h04Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:STSASatsuma Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:STSA

Kürzlich von Ihnen besucht

NASDAQI
CDD
ISE Canadian Dollar FX S...
COIN
QUICKGBP
QuickSwap
BIT
UC8337
Unicredit Bank
LSE
ARTL
Alpha Real
BIT
NSCIT2408945
European Bank for Recons...
TG
A2R2LA
Ceske Drahy
USOTC
KDXFF
Samsung Kodex200 ETF (GM)
TSXV
TPO
LSE
BK31
Bowbell Z 65
EU
BFCHA
BFCM 4.74% 24/01/26
BIT
F18895
Vontobel Financial Produ...
USOTC
ATMGF
ATCO Mining (PK)
USOTC
BFLBY
Bilfinger (PK)
AQSE
OPG.GB
Opg Power Ventures
USOTC
NBVG
Nutripure Beverages (CE)
BIT
P1ZH46
NLBNPIT1ZH46 20241220 12
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten